Janus Henderson Group PLC Bellus Health Inc. Transaction History

Janus Henderson Group PLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $66,273 - $79,175	-9,282 Reduced 0.92%	994,579 $7.16 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $1.82 Million - $2.39 Million	221,938 Added 28.38%	1,003,861 $8.25 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $2.36 Million - $3.17 Million	-264,183 Reduced 25.25%	781,923 $8.26 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $3.89 Million - $6.03 Million	-602,067 Reduced 36.53%	1,046,106 $9.65 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $2.05 Million - $2.94 Million	368,157 Added 28.76%	1,648,173 $11.3 Million
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $1.18 Million - $1.87 Million	-225,246 Reduced 14.96%	1,280,016 $10.3 Million
Q3 2021 Nov 16, 2021	SELL	$2.7 - $6.64 $1.18 Million - $2.91 Million	-438,127 Reduced 22.54%	1,505,262 $9.18 Million
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.61 $388,128 - $575,328	-124,800 Reduced 6.03%	1,943,389 $6.03 Million
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $640,699 - $968,450	211,452 Added 11.39%	2,068,189 $7.95 Million
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $4.21 Million - $6.13 Million	1,856,737 New	1,856,737 $5.64 Million
Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $498,042 - $2.8 Million	-232,730 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $834,160 - $1.05 Million	93,937 Added 67.68%	232,730 $2.4 Million
Q1 2020 May 14, 2020	BUY	$5.77 - $10.85 $604,136 - $1.14 Million	104,703 Added 307.14%	138,793 $1.39 Million
Q4 2019 Feb 18, 2020	BUY	$5.76 - $7.6 $196,358 - $259,084	34,090 New	34,090 $259,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.